| Filed On | Filing |
|---|---|
| 17 Sep 2026 |
Form 4: Meyer Robert J., Director
Granted 31,182 Stock Option (Right to Buy) |
| 17 Sep 2026 |
Form 3: Meyer Robert J., Director
No securities owned |
| 16 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 15, 2026 (the “Effective Date”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Avalyn Pharma Inc. (the “Company”), the Board appointed Robert Meyer, M... |
| 14 Aug 2026 | SCHEDULE 13G |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 11 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | SCHEDULE 13G/A |
| 01 Jul 2026 | 8-K: Entry into a Material Definitive Agreement |
| 17 Jun 2026 | 8-K: Regulation FD Disclosure |
| 03 Jun 2026 | 10-Q |
| 03 Jun 2026 | 8-K: Results of Operations and Financial Condition |
| 08 May 2026 | SCHEDULE 13D |
| 08 May 2026 | SCHEDULE 13D |
| 07 May 2026 | SCHEDULE 13G |
| 05 May 2026 |
Form 4: Novo Holdings A/S, 10% owner
Received 3,327,734 shares by conversion · Bought 555,555 shares ($10M) |
| 05 May 2026 | SCHEDULE 13G |
| 05 May 2026 |
Form 4: Fmr Llc, 10% owner
Received 2,284,535 shares by conversion |
| 04 May 2026 |
Form 4: Golden Adam H., General Counsel
Granted 254,891 Stock Option (Right to Buy) |
| 01 May 2026 |
Form 4: Carroll Jill, Director
Received 1,908,784 shares by conversion · Bought 277,778 shares ($5M) |
Loading...
